• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Top 4 Health Care Stocks That Are Preparing To Pump This Month

    2/23/24 7:50:29 AM ET
    $GRI
    $OSA
    $PBLA
    $SINT
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Medical Specialities
    Health Care
    Get the next $GRI alert in real time by email

    The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.

    The RSI is a momentum indicator, which compares a stock's strength on days when prices go up to its strength on days when prices go down. When compared to a stock's price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered oversold when the RSI is below 30, according to Benzinga Pro.

    Here’s the latest list of major oversold players in this sector, having an RSI near or below 30.

    ProSomnus, Inc. (NASDAQ:OSA)

    • On Feb. 22, ProSomnus reported successful pilot study validation of next generation remote patient monitoring device for obstructive sleep apnea. The company’s stock fell around 26% over the past five days and has a 52-week low of $0.3450 .
    • RSI Value: 29.72
    • OSA Price Action: Shares of ProSomnus gained 5.6% to close at $0.5176 on Thursday.

    Panbela Therapeutics, Inc. (NASDAQ:PBLA)

    • On Feb. 15, Panbela said it regained compliance with Nasdaq listing standards for bid price and publicly held shares requirements. The company’s stock fell around 71% over the past month. It has a 52-week low of $1.06.
    • RSI Value: 29.71
    • PBLA Price Action: Shares of Panbela Therapeutics fell 3.5% to close at $1.11 on Thursday.

    Sintx Technologies, Inc. (NASDAQ:SINT)

    • On Feb. 21, SiNtx Technologies entered into second long term supply agreement for aerospace market. The company’s stock fell around 55% over the past month and has a 52-week low of $0.13.
    • RSI Value: 29.66
    • SINT Price Action: Shares of Sintx Technologies fell 6.4% to close at $0.14 on Thursday.

    GRI Bio, Inc. (NASDAQ:GRI)

    • On Feb. 2, GRI Bio announced pricing of a $5.5 million public offering. The company’s shares lost around 21% over the past five days. The company’s 52-week low is $0.81.
    • RSI Value: 29.28
    • GRI Price Action: Shares of GRI Bio dipped 12.9% to close at $0.8450 on Thursday.

     

    Read More: Ardelyx Posts Q4 Loss, Joins MercadoLibre, Booking Holdings And Other Big Stocks Moving Lower In Friday's Pre-Market Session

    Get the next $GRI alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $GRI
    $OSA
    $PBLA
    $SINT

    CompanyDatePrice TargetRatingAnalyst
    GRI Bio Inc.
    $GRI
    12/9/2024$10.00Buy
    H.C. Wainwright
    Panbela Therapeutics Inc.
    $PBLA
    6/28/2021$10.00Buy
    Roth Capital
    More analyst ratings

    $GRI
    $OSA
    $PBLA
    $SINT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Lyons Christopher Michael bought $24,092 worth of shares (8,292 units at $2.91) (SEC Form 4)

    4 - Sintx Technologies, Inc. (0001269026) (Issuer)

    3/10/26 9:00:18 AM ET
    $SINT
    Medical/Dental Instruments
    Health Care

    Director Moyes Jay M bought $2,910 worth of shares (1,000 units at $2.91), increasing direct ownership by 33% to 4,000 units (SEC Form 4)

    4 - Sintx Technologies, Inc. (0001269026) (Issuer)

    2/25/26 9:00:02 AM ET
    $SINT
    Medical/Dental Instruments
    Health Care

    Director Anderson Mark Lewis bought $9,060 worth of shares (3,000 units at $3.02), increasing direct ownership by 20% to 18,000 units (SEC Form 4)

    4 - Sintx Technologies, Inc. (0001269026) (Issuer)

    2/19/26 9:00:04 AM ET
    $SINT
    Medical/Dental Instruments
    Health Care

    $GRI
    $OSA
    $PBLA
    $SINT
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    SINTX Technologies Appoints Ryan Elmore President to Lead Channel Expansion of Silicon Nitride Biomaterial Platforms

    Appointment supports acceleration of revenue opportunities from SiNERGY™ silicon nitride devices and antipathogenic fibrous material technologies SALT LAKE CITY, Utah, Feb. 18, 2026 (GLOBE NEWSWIRE) -- SINTX Technologies, Inc. (NASDAQ:SINT) ("SINTX" or the "Company"), an advanced ceramics and biomaterials company focused on silicon nitride (SiN) solutions for medical and other high-value applications, today announced the appointment of Ryan Elmore as President of SINTX Technologies, Inc., effective March 16, 2026. Mr. Elmore most recently served as Core Business Director at Invibio, a division of Victrex plc. With more than 15 years of experience in advanced biomaterials and medical dev

    2/18/26 8:30:00 AM ET
    $SINT
    Medical/Dental Instruments
    Health Care

    GRI Bio to Participate in the Corporate Connect Webinar Series Virtual Conference Hosted by Webull Financial

    – Live video webcast on Wednesday, February 11th at 1:00 PM EST  LA JOLLA, CA, Feb. 05, 2026 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ:GRI) ("GRI Bio" or the "Company"), a biotechnology company advancing an innovative pipeline of immune cell modulators for the treatment of inflammatory, fibrotic and autoimmune diseases, today announced that it will participate in the Corporate Connect Webinar Series hosted by Webull Financial being held virtually February 10-11, 2026. Details of the presentation are as follows:Date and Time: Wednesday, February 11, 2026 at 1:00 PM ESTPresenter: Marc Hertz, PhD, President, Chief Executive Officer and DirectorRegistration Link: Here About Webull Financial

    2/5/26 9:15:00 AM ET
    $GRI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    GRI Bio Reiterates Full Year 2025 Financial Results, Strengthens Balance Sheet and Summarizes Key Recent Highlights

    Company reported $8.2 million in cash and cash equivalents at December 31, 2025 and raised additional $6.5 million in gross proceeds in January 2026  Balance sheet strengthened to fund operations into Q1 2027 Strong Phase 2a clinical data for GRI-0621 in idiopathic pulmonary fibrosis reinforce clinical proof-of-concept and therapeutic differentiation GRI-0803 focused on autoimmune indications with high unmet need advancing through IND-enabling activities LA JOLLA, CA, Feb. 04, 2026 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ:GRI) ("GRI Bio" or the "Company"), a biotechnology company advancing an innovative pipeline of immune cell modulators for the treatment of inflammatory, fibrotic and

    2/4/26 8:45:00 AM ET
    $GRI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $GRI
    $OSA
    $PBLA
    $SINT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    H.C. Wainwright initiated coverage on GRI Bio with a new price target

    H.C. Wainwright initiated coverage of GRI Bio with a rating of Buy and set a new price target of $10.00

    12/9/24 7:50:37 AM ET
    $GRI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Roth Capital initiated coverage on Panbela Therapeutics with a new price target

    Roth Capital initiated coverage of Panbela Therapeutics with a rating of Buy and set a new price target of $10.00

    6/28/21 6:58:09 AM ET
    $PBLA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Maxim Group initiated coverage on Panbela Therapeutics with a new price target

    Maxim Group initiated coverage of Panbela Therapeutics with a rating of Buy and set a new price target of $8.00

    3/16/21 8:15:44 AM ET
    $PBLA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $GRI
    $OSA
    $PBLA
    $SINT
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Lyons Christopher Michael bought $24,092 worth of shares (8,292 units at $2.91) (SEC Form 4)

    4 - Sintx Technologies, Inc. (0001269026) (Issuer)

    3/10/26 9:00:18 AM ET
    $SINT
    Medical/Dental Instruments
    Health Care

    Director Moyes Jay M bought $2,910 worth of shares (1,000 units at $2.91), increasing direct ownership by 33% to 4,000 units (SEC Form 4)

    4 - Sintx Technologies, Inc. (0001269026) (Issuer)

    2/25/26 9:00:02 AM ET
    $SINT
    Medical/Dental Instruments
    Health Care

    Director Anderson Mark Lewis bought $9,060 worth of shares (3,000 units at $3.02), increasing direct ownership by 20% to 18,000 units (SEC Form 4)

    4 - Sintx Technologies, Inc. (0001269026) (Issuer)

    2/19/26 9:00:04 AM ET
    $SINT
    Medical/Dental Instruments
    Health Care

    $GRI
    $OSA
    $PBLA
    $SINT
    SEC Filings

    View All

    SiNtx Technologies Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

    8-K - Sintx Technologies, Inc. (0001269026) (Filer)

    2/18/26 8:35:38 AM ET
    $SINT
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by GRI Bio Inc.

    SCHEDULE 13G/A - GRI Bio, Inc. (0001824293) (Subject)

    2/13/26 4:43:01 PM ET
    $GRI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    GRI Bio Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - GRI Bio, Inc. (0001824293) (Filer)

    2/4/26 8:48:49 AM ET
    $GRI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $GRI
    $OSA
    $PBLA
    $SINT
    Leadership Updates

    Live Leadership Updates

    View All

    SINTX Technologies Appoints Ryan Elmore President to Lead Channel Expansion of Silicon Nitride Biomaterial Platforms

    Appointment supports acceleration of revenue opportunities from SiNERGY™ silicon nitride devices and antipathogenic fibrous material technologies SALT LAKE CITY, Utah, Feb. 18, 2026 (GLOBE NEWSWIRE) -- SINTX Technologies, Inc. (NASDAQ:SINT) ("SINTX" or the "Company"), an advanced ceramics and biomaterials company focused on silicon nitride (SiN) solutions for medical and other high-value applications, today announced the appointment of Ryan Elmore as President of SINTX Technologies, Inc., effective March 16, 2026. Mr. Elmore most recently served as Core Business Director at Invibio, a division of Victrex plc. With more than 15 years of experience in advanced biomaterials and medical dev

    2/18/26 8:30:00 AM ET
    $SINT
    Medical/Dental Instruments
    Health Care

    SINTX Technologies Appoints Gregg R. Honigblum as Chief Strategy Officer

    Seasoned Healthcare Executive to Lead Strategic Growth Initiatives Salt Lake City, UT, Nov. 19, 2024 (GLOBE NEWSWIRE) -- SINTX Technologies, Inc. (NASDAQ:SINT) ("SINTX" or the "Company"), an advanced ceramics company that develops and commercializes materials, components, and technologies for medical and technical applications, is pleased to announce the appointment of Gregg R. Honigblum as Chief Strategy Officer (CSO). In this role, Mr. Honigblum will oversee driving corporate strategy to support SINTX's growth initiatives and enhancing investor relations. Mr. Honigblum brings over 35 years of experience as an executive for emerging growth companies, specializing in the healthcare secto

    11/19/24 6:00:00 AM ET
    $SINT
    Medical/Dental Instruments
    Health Care

    Connect Biopharma Announces New Leadership and Chair of the Board of Directors

    Industry leader Barry Quart, Pharm.D. appointed as Chief Executive Officer succeeding Zheng Wei, Ph.D., who will remain on the Board of Directors and serve as an advisor to assist with the transitionExperienced life science executive David Szekeres appointed as PresidentKleanthis G. Xanthopoulos, Ph.D. appointed as Chair of the Board of Directors SAN DIEGO, CA and TAICANG, China, June 12, 2024 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (NASDAQ:CNTB) (Connect or the Company), a U.S.-headquartered, global clinical-stage biopharmaceutical company dedicated to improving the lives of patients with chronic inflammatory diseases through the development of therapies derived from T cel

    6/12/24 4:15:00 PM ET
    $CNTB
    $GRI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $GRI
    $OSA
    $PBLA
    $SINT
    Financials

    Live finance-specific insights

    View All

    SINTX Reports Pivotal Third Quarter Business Update and Financial Highlights Driven by FDA Clearance, Product and IP Portfolio Expansions and Increased Operational Efficiencies

    Company underscores its strengthened liquidity, cost reductions, and first revenue recorded from OsseoSculpt™  SALT LAKE CITY, Utah, Nov. 13, 2025 (GLOBE NEWSWIRE) -- SINTX Technologies, Inc. (NASDAQ:SINT) ("SINTX" or the "Company"), an advanced ceramics and biomaterials company focused on silicon-nitride–based medical technologies, today provided a business update reporting third quarter financial results in conjunction with the filing the Company's Form 10-Q for the quarter ended September 30, 2025. During the third quarter and subsequent weeks, SINTX advanced a focused commercialization plan centered on infection-resistant silicon nitride devices and polymer composites, while tighteni

    11/13/25 8:00:00 AM ET
    $SINT
    Medical/Dental Instruments
    Health Care

    SINTX Technologies Acquires SiNAPTIC Surgical Assets and IP to Expand into $1.3B Foot and Ankle Fusion Market

    Strategic Acquisition Brings Patented Implant Designs, Seasoned Executive Team, and Near-Term Commercial Opportunities SALT LAKE CITY, Utah, June 24, 2025 (GLOBE NEWSWIRE) -- SINTX Technologies, Inc. (NASDAQ:SINT) ("SINTX" or the "Company"), an advanced ceramics company focused on medical device innovation, today announced that it has executed a Definitive Agreement to acquire the surgical business assets of SiNAPTIC Holdings, LLC, a privately held company focused on silicon nitride ceramic manufacturing and innovation. This transaction is a significant milestone in SINTX's strategy to acquire a potential competitor and drive commercial revenue growth and expand its product portfolio in t

    6/24/25 8:30:00 AM ET
    $SINT
    Medical/Dental Instruments
    Health Care

    Panbela to Host Third Quarter 2024 Earnings Conference Call on November 14, 2024

    MINNEAPOLIS, Oct. 31, 2024 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (OTCQB:PBLA), ("Panbela"), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, today announced that it will host a conference call on November 14, 2024, at 4:30 PM Eastern Time to discuss results for its third quarter ended September 30, 2024. Conference Call InformationToll Free: 877-545-0320International: 973-528-0002Participant Access Code: 370494Webcast Link: https://www.webcaster4.com/Webcast/Page/2556/51548 Conference Call Replay InformationToll Free: 877-481-4010International: 919-882-2331Replay Passcode: 51548Webcast Replay: https://www.

    10/31/24 8:00:00 AM ET
    $PBLA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $GRI
    $OSA
    $PBLA
    $SINT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by SiNtx Technologies Inc.

    SC 13G/A - Sintx Technologies, Inc. (0001269026) (Subject)

    11/14/24 7:25:52 PM ET
    $SINT
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13D filed by Panbela Therapeutics Inc.

    SC 13D - Panbela Therapeutics, Inc. (0001029125) (Subject)

    10/29/24 7:40:55 PM ET
    $PBLA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by SiNtx Technologies Inc.

    SC 13G - Sintx Technologies, Inc. (0001269026) (Subject)

    4/1/24 4:17:43 PM ET
    $SINT
    Medical/Dental Instruments
    Health Care